Turing Rejects $100 Million Offer For Daraprim By: Benzinga via Benzinga May 10, 2017 at 11:32 AM EDT Let’s talk Daraprim — again. The controversially pricey drug that set regulators on their toes and prompted critical ... Read More >> Related Stocks: Gsk Plc ADR Mylan Nasdaq Biotechnology Ishares ETF Valeant Pharmaceuticals International, Inc.